Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: The Indiana University experience

M. Behnia, R. Foster, L. H. Einhorn, J. Donohue, C. R. Nichols

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non- seminomatous germ cell tumours. Between 1985 and 1995, 86 patients with pathological stage II non-seminomatous testicular cancer were treated with two cycles of BEP. At retroperitoneal lymph node dissection (RPLND) 49 patients (57%) had pathological stage II(A) (microscopic nodal metastases) and 37 (43%) had stage II(B) (gross nodal metastases). After RPLND, the patients received bleomycin, 30 units weekly for 8 weeks, etoposide (100 mg/m2) and cisplatin (20 mg/m2) each for 5 days every 28 days for two cycles as adjuvant chemotherapy. 4 patients were lost to follow-up. 10 patients (12%) developed granulocytopenic fever during their chemotherapy. Of the 82 evaluable patients all remained with no evidence of disease except for a single patient with a cervical nodal relapse of teratoma. This was resected and he remains disease free. Median follow-up has been 85 months (range: 42- 173 months). In patients with fully resected stage II non-seminomatous germ cell tumour, two cycles of BEP were almost universally effective in preventing relapse. (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)472-475
Number of pages4
JournalEuropean Journal of Cancer
Volume36
Issue number4
DOIs
StatePublished - Mar 1 2000

Keywords

  • Adjuvant
  • Bleomycin
  • Cisplatin
  • Etoposide
  • Testicular cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: The Indiana University experience'. Together they form a unique fingerprint.

  • Cite this